MedWatch

French reforms and US vaccinations benefit Demant in corona-struck times

Demant's Tuesday upgrade was highly driven by the French market but the firm has also advanced in the rest of the world, and the hearing aid firm's CEO Søren Nielsen is confident that Demant will be able to keep up the pace for the rest of the year.

Demant President & CEO Søren Nielsen | Photo: Kenneth Lysbjerg Koustrup/ERH

Demant has raised its guidance for 2021 based on looking back on the first three months, rather than ahead to the next nine, says Søren Nielsen, CEO of Demant, to MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs